**TCT-298**

Six-month Intravascular Ultrasound Analysis of the DESolve FIM Trial with a Novel PLLA-based Fully Biodegradable Drug-eluting Scaffold

Jose Costa Jr,1 John Ormiston,1 Alexandre Abizaid,2 James Stewart,2 Daniel Chamié,2 Mark Webster,3 John Yan,3 Vinyak Bahh,4 Lynn Morrison,3 Sara Toyolo,5 Stefan Verheyen1

1Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 2Associate Professor, University of Auckland Medical School, Auckland, New Zealand, 3Visiting Professor Columbia University, Sao Paulo, Brazil, 4Auckland City Hospital, Auckland, New Zealand, 5Dante Pazzanese, Sao Paulo, Brazil, 6Elixir Medico Corp, Sunnyvale, CA, 7Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp, Belgium

**Background:** The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a biodegradable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has demonstrated potent anti-proliferative properties in two first-in-man (FIM) trials using Elixir’s metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold.

**Methods:** The DESolve FIM trial enrolled 15 patients, treated with a single 3.0x14 mm DESolve at 3 centers. IVUS was performed at the end of the procedure and repeated at six-month invasive follow-up. Complete and adequate IVUS images at baseline and follow-up were obtained for 11 cases. Serial changes in vessel volume, scaffold area and the degree of NIH formation were assessed. All analyses were performed by an independent core laboratory.

**Results:** From baseline to 6 months, IVUS showed a small increase in scaffold mean area (from 5.35 ± 0.78 mm² to 5.61 ± 0.81 mm²). Additionally, there was no significant change in vessel volume (from 148.0 ± 37.0 mm³ to 150.03 ± 35.38 mm³) or area, demonstrating the absence of constrictive or expansive remodeling. There was very low neointimal volume (5.6 ± 2.8 mm³) and % scaffold obstruction (7.18 ± 3.37%), and no cases of incomplete strut apposition.

**Conclusions:** The DESolve scaffold demonstrated a unique property of expansion and no chronic recoil from baseline to follow-up. Results at 6 months showed effective neointimal suppression and no late strut malapposition thus suggesting a very efficacious and novel bioresorbable scaffold.

**TCT-299**

Impact of Baseline Peri-Stent Plaque Volume on Positive Vessel Remodeling after Implantation of Paclitaxel Eluting Stents: A Pooled Volumetric Intravascular Ultrasound Analysis

Kenji Sakamot1, Katsushia Waseda1, Hideki Kitahara2, Ryotaro Yamada1, Ching-Chang Huang1, Paul Yock1, Peter Fitzgerald1, Yasuhito Honda1

1Stanford University Medical Center, Stanford, CA

**Background:** Positive vessel remodeling, caused by an increase in peri-stent plaque volume during follow-up, has frequently been demonstrated in clinical studies of paclitaxel-eluting stents (PES). Histopathologic studies have also shown an association of positive remodeling with vessel inflammation, possibly related to the occurrence of very late stent thrombosis. This study aimed to investigate the determinants of vessel remodeling in patients treated with PES as assessed by IVUS.

**Methods:** Serial (post-procedure and 8-9 months follow-up) volumetric IVUS data were analyzed in 227 de novo coronary lesions electively treated with PES. Volume index (VI) was defined as volume/length (mm³/mm). Peri-stent plaque VI was standardized by stent VI (%PVI). Vessel remodeling during follow-up was assessed as a change of peri-stent plaque VI per stent VI. Morphologic properties with a p-value<0.10 on univariate analysis were inserted into multivariate models.

**Results:** Overall, the change of vessel VI during follow-up was 5.0±8.1% (range: -21.7% to +56.1%), resulted from a significant increase of %PVI (95.9±29.9% to 103.9±28.9%, p<0.0001). Among IVUS parameters at post-procedure, vessel VI and %PVI had significant inverse correlations with positive vessel remodeling (p=0.002, p=0.0002, respectively). In multivariate analysis, less %PVI at post-procedure was independently associated with positive vessel remodeling during follow-up (p=0.02).

**Conclusions:** This pooled IVUS analysis identified thinner peri-stent plaque surrounding PES at baseline as a predictor of larger positive vessel remodeling during follow-up. This may reflect the differential mechanical compliance and/or increased drug infiltration into the deep vessel wall structure in the setting of less underlying plaque behind the stent.

**TCT-300**

Differential Prognostic Impact of Intravascular Ultrasound Utilization According to Implanted Stent Length

Jung-Min Ahn1, Shin-Eui Yoon1, Seung Mo Kang2, Hyun Woo Park3, Uk Joo1, Young-Rak Choi4, Gyu-Min Park5, Won-Jang Kim4, Jong-Young Lee4, Duk-Woo Park6, Soo-Jin Kang7, Seung-Whan Lee7, Young-Hak Kim7, Cheol Whan Lee8, Seong-Wook Park9, Seung-Jung Park9

1Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of

**Background:** It is unknown whether IVUS utilization during percutaneous coronary intervention (PCI) may modify the stent length effect on clinical outcomes. We sought to find differential prognostic impact of intravascular ultrasound (IVUS) utilization according to the implanted stent length.

**Methods:** Between April 2008, and June 2010, we enrolled 3244 consecutive patients undergoing single or overlapping stent implantation at 46 academic or community hospitals in Korea. The primary endpoint was a composite of death, myocardial infarction, or target vessel revascularization (MACE). Study population was divided by the tertiles of implanted stent length and IVUS utilization.

**Results:** After adjustment for significant covariates, implanted stent length was not significantly associated with the risk of MACE in IVUS group (hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.97-1.20, p=0.16), whereas implanted stent length was significantly associated with the risk of MACE in no IVUS group (HR 1.13, 95% CI 1.01-1.28, p=0.042). In addition, in patients with implanted stent length of ≤22mm (N=988), the risk of MACE was not significantly different between IVUS group and no IVUS group (HR 1.06, 95% CI 0.50-2.28, p=0.88). By contrast, in patients with longer implanted stent length, the risk of MACE was significantly lower in IVUS group than in no IVUS group (HR 0.47, 95% CI 0.24-0.92, p=0.027 for ≥23-32mm [N=1109], HR 0.57, 95% CI 0.33-0.98, p=0.042 for ≥33mm [N=1137]).

**Conclusions:** IVUS utilization may attenuate the detrimental effect of the increase of implanted stent length, supporting the favor of IVUS utilization, particularly during PCI with the long stent implantation.

**TCT-301**

Feasibility and Results of Novel Side Branch Evaluation by Reconstructed 3-Dimensional Optical Coherence Tomography. Matched Analysis of Baseline and 12-month follow-up in Native, Jailed and Opened Side Branches

Niels Holm1, Shengxiu Tu2, Rasmus Christensen1, Trine Ørhøj1, Evald Høj Christiansen 1

1Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Leiden, Netherlands, 2Aarhus University Hospital, Skejby, Aarhus, Denmark

**Background:** Assessment of the side branch (SB) ostium by angiography and 2D optical coherence tomography (OCT) is challenging. This is the first presentation of ostial SB evaluation by reconstructed side branch OCT. This study is aimed to present the feasibility and results of side branch OCT.

**Methods:** The study was a substudy to the SORT-OUT V OCT study comparing a sirolimus eluting durable polymer stent (Cypher Select+®, Cordis, US) and a biolimus eluting biodegradable polymer stent (Nobori, Terumo, JP). The SB ostium was evaluated in all SBs visible on both baseline and 12-month follow-up OCT. Each SB ostium was reconstructed in 3D by the main vessel OCT acquisition using QAngioOCT prototype (Medis medical imaging systems, NL). The minimal luminal area (MLA) was assessed up to one millimeter into the SB. The measurement (plane of the cut plane), was reconstructed perpendicular to the SB centerline. In case of neointimal bridging over the SB ostium, the areas of the individual ostia of the same SB were summed.

**Results:** Matched baseline and OCT data was available in 96 patients. At baseline 208 SBs were detected and of these were 107 (51%) in-stent SBs. SBs were not analyzable due to wire shadow in 49 (23%) SBs and due to impaired image quality in 26 (12.5%) of SBs.
Total number of matched SBs for analysis was 158, 72 in-stent and 66 in native vessels. These SBs had undergone balloon-dilation and were grouped with jailed SBs. Analysis of the entire first millimeter was possible in 58% of analyzed SBs. Mean native ostial area was increased from 1.67±1.61 mm² at baseline to 1.74±1.85 mm² (p<0.044) at FU. Average in-stent ostial area was increased from 1.30±1.42 mm² at baseline to 1.52±1.54 mm² (p<0.06) at FU. In-stent ostial area gain between baseline and FU for Cypher was 0.32±0.36 mm² vs. 0.08±0.09 mm² (p=0.032) for Nobori. Neointimal bridging occurred in 13% (10%) of all assessed FU SBs. Intra-observer mean difference was 0.001±0.12 mm² and inter-observer mean difference was 0.012±0.23 mm².

**Conclusions:** OSB evaluation by 3D reconstruction of main vessel OCT acquisition is feasible when the ostium is visible and can be performed with high intra- and interobserver agreement. DES-jailed SBs tended to improve in ostial MLA at 12-month FU while mean MLA in native SB ostia remained unchanged.

**TCT-302**

**Evaluation of the Novel DESolve Myolimus-Eluting Bioresorbable Coronary Scaffold System for Treatment of De Novo Coronary Arteries: Six-Month Optical Coherence Tomography Results from the DESolve FIM Trial**

Daniel Chamie1, Jose Costa Jr2, Alexandre Abizaid3, Mark Webster4, James Stewart5, Ricardo Costa, John Yiu6, Vinayak bhat8, Lynn Morrison7, Siwicki Taylor1, John Ormiston9, Stefan Verheyen2.

1Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 2Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil, 3Visiting Professor Columbia University, Sao Paulo, Brazil, 4Auckland City Hospital, Auckland, New Zealand, 5Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 6Severance Hospital, Seoul, Korea, Republic of, 7Yonsei Cardiovascular Research Institute, Seoul, Korea, Republic of, 8Associate Professor, University of Auckland Medical School, Auckland, New Zealand, 9Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, 10Antwerp, Belgium.

**Background:** The DESolve Bioresorbable Scaffold (BS) is a novel PILLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus (3 mg/mm of scaffold length). Myolimus, a macrolyclic lactone mTOR inhibitor, has shown potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixa’s metallic coronary stents. We aim to present the OCT results of the FIM evaluation of this novel BS.

**Methods:** 15 pts treated with a single 3.0x14 mm DESolve at 3 centers were enrolled. Serial (baseline and 6-month follow-up) OCT was available for 10 pts. All images were analyzed by an independent core laboratory at 0.6-mm interval. At baseline, scaffold malapposition and scaffold structural discontinuity (qualitatively defined as ≥ 2 struts overhanging each other in the same angular sector of the lumen, or by isolated struts floating inside the lumen in complete misalignment with the surrounding struts) were assessed. At follow-up, serial changes in lumen and scaffold dimensions and degree of NIH formation on top of the struts were assessed. Frequency of covered struts and NIH thickness on top of each strut were also examined. Scaffold and strut malapposition were serially assessed at the cross-section and strut levels respectively.

**Results:** At baseline, no signs of structural discontinuity were observed at the cross-section level inspection. Scaffold area was maintained over time with no evidence of scaffold malapposition from baseline (2.66±0.68 mm²) to 6-month FU (2.76±0.85 mm², p<0.01) or NIH area measured 0.71±0.36 mm², with 13.16±5.59% obstruction of the scaffold area. At 6 months, 2,575 struts were analyzed and 98.7% were covered with a very thin NIH (0.12±0.04 mm). Scaffold malapposition was observed in only 1 cross-section of 1 strut. Rate of malapposed struts per scaffold varied from 2.01% (0.12% and 0.12%) over time (p<0.06).

**Conclusions:** The DESolve Scaffold exhibited maintenance of its structural integrity upon deployment, proproliferating excellent mechanical support without chronic recoil. At 6 months, it demonstrated effective NIH suppression without compromising tissue coverage of the polymeric struts, with virtually complete resolution of acute scaffold malapoposition.

**TCT-303**

**Predictors Of Acute And Late Persistent Stent Malapposition After Percutaneous Coronary Intervention: A Follow-up Optical Coherence Tomography Study**

Eui Im1, Byeong-Keuk Kim2, Jung-Sun Kim3, Dong-Ho Shin4, Young-Guk Ko5, Donghoon Choi3, Yang-Soo Jang6, Myeong-Ki Hong7.

1Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 2Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil, 3Visiting Professor Columbia University, Sao Paulo, Brazil, 4Auckland City Hospital, Auckland, New Zealand, 5Younsei University, Seoul, Korea, Republic of, 6Severance Hospital, Seoul, Korea, Republic of, 7Yonsei Cardiovascular Research Institute, Seoul, Korea, Republic of.

**Background:** There are limited data about predictors of acute stent malapposition (ASM) and late persistent stent malapposition (LPSM) detected by optical coherence tomography (OCT).

**Methods:** A total of 252 patients (257 lesions) who underwent both post-stent and follow-up OCT were enrolled for analysis. Malapposed struts on post-stent OCT were identified and those struts were re-evaluated on follow-up OCT. Various clinical, angiographic, and OCT parameters were evaluated to identify predictors of ASM and LPSM.

**Results:** On post-stent OCT, 169 lesions (66%) showed ASM with malapposed strut % overhanging each other in the same angular sector of the lumen, or by isolated struts floating inside the lumen in complete misalignment with the surrounding struts) were considered uncovered, while stents with ≥5% uncovered struts were considered malapposed.

**Conclusions:** Intervals since implantation were similar among the different clinical presentations (ACS: median 65 months (range 22-201), SA: 76.5 months (31-168), asymptomatic: 5.59% obstruction of the scaffold area. Neointimal bridging occurred in 13 patients the culprit of stable angina (SA), whereas 22 patients had no symptoms attributed to the stented lesion (SA and 31.8% in the asymptomatic group [p=0.39]). The incidence of neointimal malapposition was comparable among the three groups (ACS: 33.3%, SA: 15.4%, asymptomatic: 22.7%; p=0.39).

**Conclusions:** Not only impaired vascular healing, but neatherosclerosis and neointimal rupture as well, seem to contribute significantly in the pathogenesis of late stent failure, being associated with symptomatic presentation late after coronary stent implantation.

**TCT-304**

**Neatherosclerosis And Impaired Vascular Healing Are Associated With Clinical Presentation Late After Coronary Stent Implantation. An Optical Coherence Tomography Study**


1Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands, 2Hippokration Hospital, Athens, Greece.

**Background:** Both impaired vascular healing and proliferative tissue response, including neatherosclerosis, play a role in the pathogenesis of late stent failure, presenting either as restenosis or stent thrombosis. We investigated the association of neatherosclerosis and neointimal rupture with clinical presentation in patients late after coronary stent implantation by optical coherence tomography (OCT).

**Methods:** From 1/1/2007 to 31/1/2012, 74 patients from two institutions underwent OCT assessment of a coronary stent implanted at least 18 months prior to examination. In 39 of the patients the studied stent was the culprit of acute coronary syndrome (ACS) (myocardial infarction n=34; unstable angina n=5), in 13 patients the culprit of stable angina (SA), whereas 22 patients had no symptoms attributed to the stented stent (asymptomatic). Stents containing ≥5 frames (1mm) with ≥30% uncovered struts were considered uncovered, while stents with ≥5% malapposed struts were considered malapposed.

**Results:** Between LPSM and resolved-ASM lesion during 2-year follow-up (3.6% vs. 2.6%, respectively, p=0.66).

**Conclusions:** In this OCT study, calcification and long stent length were the independent predictors of ASM. The Stents containing ≥5 frames (1mm) with ≥30% uncovered struts were considered uncovered, while stents with ≥5% malapposed struts were considered malapposed.

**TCT-305**

**Correlation Between Predicted To Observed Coronary Drug-Eluting Stent (DES) Expansion As Determined By Intravascular Ultrasound (IVUS) And Optical Coherence Tomography (OCT): Variance Between Stent Platforms and Impact of Lesion Characteristics**

Vikrant Jagadeesan1, Mark Gajjar2, Linda Lee3, Sandeep Nathan4.

1University of Chicago Medical Center, Darien, IL, 2University of Chicago Medical Center, Chicago, IL.

**Background:** Manufacturer-predicted stent expansion is based on in vitro testing. Actual expansion is related to stent architecture, lesion characteristics, etc. We evaluated the relationships between these variables on coronary DES expansion via IVUS. Actual expansion is related to stent architecture, lesion characteristics, etc. We evaluated the relationships between these variables on coronary DES expansion via IVUS.

**Methods:** 1,652 IVUS frames were acquired and blindly analyzed in 56 lesions post-DES via Volcano EagleEye Platinum 20 MHz IVUS. DES studied were Medtronic Endeavor (n=32, 24 mm), and Resolution (n=12, 22 mm), and Resolute (3.5 mm) deployed at 16-22 ATM after nominal balloon pre-dilatation. Expansion deficit (ED), % was the ratio of observed to predicted average stented diameter.

**Results:** DES were less expanded than predicted (ED = -10.5%, p<0.001) but none expanded significantly more compared with deployment. Mean ED was highest in Endeavor vs Xience or Resolution (-11.8% vs. -6.0%, p<0.001, Fig 1). 98.4% of Resolution frames were under-expanded vs. 93.7% Endeavor frames and 80.4% Xience (p<.001). ED was greater in ACS vs. non-ACS (-11.2% vs. -10.2%, p=0.02) and LAD